Your browser doesn't support javascript.
loading
Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
Lingshu Wang; Tongqing Zhou; Yi Zhang; Eun Sung Yang; Chaim A. Schramm; Wei Shi; Amarendra Pegu; Olamide K. Oloninyi; Amy Ransier; Samuel Darko; Sandeep R. Narpala; Christian Hatcher; David R. Martinez; Yaroslav Tsybovsky; Emily Phung; Olubukola M. Abiona; Evan M. Cale; Lauren A. Chang; Kizzmekia S. Corbett; Anthony T. DiPiazza; Ingelise J. Gordon; Kwanyee Leung; Tracy Liu; Rosemarie D. Mason; Alexandra Nazzari; Laura Novik; Adam S. Olia; Tyler Stephens; Christopher D. Stringham; Chloe Adrienna Talana; I-Ting Teng; Danielle Wagner; Alicia T. Widge; Baoshan Zhang; Mario Roederer; Julie E. Ledgerwood; Tracy J. Ruckwardt; Martin R. Gaudinski; Ralph S. Baric; Barney S. Graham; Adrian B. McDermott; Daniel C. Douek; Peter D. Kwong; John R. Mascola; Nancy J. Sullivan; John Misasi.
Afiliación
  • Lingshu Wang; National Institutes of Health
  • Tongqing Zhou; National Institutes of Health
  • Yi Zhang; National Institutes of Health
  • Eun Sung Yang; National Institutes of Health
  • Chaim A. Schramm; National Institutes of Health
  • Wei Shi; National Institutes of Health
  • Amarendra Pegu; National Institutes of Health
  • Olamide K. Oloninyi; National Institutes of Health
  • Amy Ransier; National Institutes of Health
  • Samuel Darko; National Institutes of Health
  • Sandeep R. Narpala; National Institutes of Health
  • Christian Hatcher; National Institutes of Health
  • David R. Martinez; The University of North Carolina at Chapel Hill
  • Yaroslav Tsybovsky; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research
  • Emily Phung; National Institutes of Health
  • Olubukola M. Abiona; National Institutes of Health
  • Evan M. Cale; National Institutes of Health
  • Lauren A. Chang; National Institutes of Health
  • Kizzmekia S. Corbett; National Institutes of Health
  • Anthony T. DiPiazza; National Institutes of Health
  • Ingelise J. Gordon; National Institutes of Health
  • Kwanyee Leung; National Institutes of Health
  • Tracy Liu; National Institutes of Health
  • Rosemarie D. Mason; Vaccine Research Center, NIAID, NIH
  • Alexandra Nazzari; National Institutes of Health
  • Laura Novik; National Institutes of Health
  • Adam S. Olia; National Institutes of Health
  • Tyler Stephens; Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research
  • Christopher D. Stringham; National Institutes of Health
  • Chloe Adrienna Talana; National Institutes of Health
  • I-Ting Teng; National Institutes of Health
  • Danielle Wagner; National Institutes of Health
  • Alicia T. Widge; National Institutes of Health
  • Baoshan Zhang; National Institutes of Health
  • Mario Roederer; Vaccine Research Center
  • Julie E. Ledgerwood; National Institutes of Health
  • Tracy J. Ruckwardt; National Institutes of Health
  • Martin R. Gaudinski; National Institutes of Health
  • Ralph S. Baric; University of North Carolina at Chapel Hill
  • Barney S. Graham; National Institutes of Health
  • Adrian B. McDermott; National Institutes of Health
  • Daniel C. Douek; NIH Vaccine Research Center
  • Peter D. Kwong; National Institute of Allergy and Infectious Diseases
  • John R. Mascola; Vaccine Research Center, NIAID, NIH
  • Nancy J. Sullivan; National Institutes of Health
  • John Misasi; National Institutes of Health
Preprint en En | PREPRINT-BIORXIV | ID: ppbiorxiv-432969
ABSTRACT
The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are resistant to therapeutic antibodies highlights the need for continuing discovery of broadly reactive antibodies. We identify four receptor-binding domain targeting antibodies from three early-outbreak convalescent donors with potent neutralizing activity against 12 variants including the B.1.1.7 and B.1.351 VOCs. Two of them are ultrapotent, with sub-nanomolar neutralization titers (IC50 <0.0006 to 0.0102 g/mL; IC80 < 0.0006 to 0.0251 g/mL). We define the structural and functional determinants of binding for all four VOC-targeting antibodies, and show that combinations of two antibodies decrease the in vitro generation of escape mutants, suggesting potential means to mitigate resistance development. These results define the basis of therapeutic cocktails against VOCs and suggest that targeted boosting of existing immunity may increase vaccine breadth against VOCs. One Sentence SummaryUltrapotent antibodies from convalescent donors neutralize and mitigate resistance of SARS-CoV-2 variants of concern.
Licencia
cc0
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2021 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-BIORXIV Idioma: En Año: 2021 Tipo del documento: Preprint